Thread by @joshuamcclure

Maxwell Biosciences is developing the “One Drug for Many Bugs” CLAROMER™ biotechnology - preclinically active against all tested variants of SARS-CoV-2 and Influenza. A NIAID-funded Syrian Hamster study showed full protection against the symptoms of #COVID & possibly #LongCOVID.

How It Works

CLAROMER drug candidates literally explode the membrane that surrounds all enveloped viruses (all coronaviruses, influenza, herpes, many others) - destroying the virus. Photographic proof is below from UT Medical Branch using an electron microscope.

A Broad Spectrum Target

Viruses - including #COVID - inherit their membrane from the infected host cell, and bring it with them like camouflage. That membrane is marked for destruction by the immune system and that marker - phosphatidylserine - is what CLAROMERS target.

Safety First

Multiple animal studies (mouse, rat and Syrian Hamster) show CLAROMERS are well tolerated, nontoxic, and not inflammatory. These may help us qualify for FDA human trials scheduled for 2023.

The CLAROMER platform produces precision engineered, synthetic biomimetic compounds: low molecular weight, non-peptide, stable drug candidates that mimic and improve upon functions of human peptides. The impact is mind blowing, especially immune peptides. #LongCOVID #COVID

CLAROMERS mimic the core human immune peptide - Human Cathelicidin Antimicrobial Peptide ("CAMP") - is stimulated by #VitaminD and which is highly correlated to #COVID survival.